Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
These data further support the validation of the angiome biomarker assay and its application as an integrated biomarker in clinical trial testing.
Authors
- Elise C. Kohn (ORCID: https://orcid.org/0000-0002-8631-9762)
- Alexander B. Sibley (ORCID: https://orcid.org/0000-0003-4552-1865)
- Kouros Owzar (ORCID: https://orcid.org/0000-0002-3340-1287)
- Lauren E. Howard (ORCID: https://orcid.org/0000-0003-3355-4483)
- Yingmiao Liu (ORCID: https://orcid.org/0000-0003-3516-5844)
- Andrew B. Nixon (ORCID: https://orcid.org/0000-0003-3971-2964)
- Herbert I. Hurwitz (ORCID: https://orcid.org/0000-0003-3242-9197)
- Jing Lyu
- Mark D. Starr (ORCID: https://orcid.org/0009-0003-9664-6235)
- S. Percy Ivy (ORCID: https://orcid.org/0000-0001-7747-072X)
- James L. Abbruzzese (ORCID: https://orcid.org/0000-0001-9223-2965)
- Jiatong Li (ORCID: https://orcid.org/0000-0003-0084-2470)
- John C. Brady
- Christy Arrowood
Institutions
- Duke University (US)
- Yale University (US)
- University of New Haven (US)
- Clinical Research Institute (US)
- National Cancer Institute (MY)
- National Cancer Institute (US)
- University of California, Davis (US)
Publication Details
- Journal
- Cancer Epidemiology Biomarkers & Prevention
- Published
- 2024-10-14
- DOI
- https://doi.org/10.1158/1055-9965.epi-24-0644
- Primary Topic
- Advanced Proteomics Techniques and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Sanofi
- Division of Cancer Prevention, National Cancer Institute
- Genentech
- National Cancer Institute